Preliminary evidence for developing safe and efficient fecal microbiota transplantation as potential treatment for aged related cognitive impairments
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Background: Recent studies have reported that gut microbiota is closely associated with cognitive fuction. Fecal microbiota transplantation (FMT) may be a potential treatment for cognitive impairment, but its efficacy in patients with cognitive impairment is unknown. Objectives: This study aimed to investigate the safety and efficacy of FMT for cognitive impairment treatment. Methods: Five patients aged 54–80 years (three women) were enrolled in this single-arm clinical trial from July 2021 to May 2022. The Montreal Cognitive Assessment-B (MoCA-B), Activities of Daily Living (ADL), and the cognitive section of the Alzheimer’s Disease Assessment Scale (ADAS-Cog) were assessed at days 0, 30, 60, 90, and 180. Additionally, stool and serum samples were obtained twice before FMT was administered and six months after the treatment. The structure of fecal microbiota was analyzed by 16S RNA gene sequencing. Serum samples were analyzed for metabolomics and lipopolysaccharide (LPS)-binding proteins by liquid chromatography-mass spectrometry and enzyme-linked immunosorbent assay, respectively. Safety was assessed based on adverse events, vital signs, and laboratory parameters during FMT and the follow-up period. Results: The MoCA, ADL, and ADAS-Cog scores of patients with mild cognitive impairment (patients C and E) after FMT were improved or maintained compared with those before transplantation. However, patients with severe cognitive impairment (patients A, B, and D) had no worsening of cognitive scores. Fecal microbiota analysis showed that FMT changed the structure of gut microbiota. The results of serum metabolomics analysis suggested that there were significant changes in the serum metabolomics of patients after FMT, with 7 up-regulated and 28 down-regulated metabolites. 3b,12a-dihydroxy-5a-cholanoic acid, 25-acetylvulgaroside, deoxycholic acid, 2(R)-hydroxydocosanoic acid, and P-anisic acid increased, while bilirubin and other metabolites decreased. KEFF pathway analysis indicated that the main metabolic pathways were bile secretion and choline metabolism in cancer. No adverse effects were reported throughout the study. Conclusions: In this pilot study, FMT could maintain and improve cognitive function in mild cognitive impairment by changing gut microbiota structure and affecting serum metabolomics. Fecal bacteria capsules were safe. However, further studies are needed to evaluate the safety and efficacy of fecal microbiota transplantation. ClinicalTrials.gov Identifier: CHiCTR2100043548.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Subsequent clinical trials have indicated that cognitive and behavioural improvements could be achieved through fecal microbiota transplantation (FMT) in patients with mild cognitive impairment as well as those suffering from PD.76,77”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [76]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
The global prevalence of dementia: a systematic review and metaanalysis.
Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., & Ferri, C. P. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.007 · Cited by 4,941 · cited 1×
“6 million people worldwide suffered from dementia in 2010, and the number is expected to reach 115 million by 2050 (Prince et al., 2013).”
BackgroundQuerfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569 · cited 1×
“Cognitive impairment is the main clinical manifestation of dementia (Owen et al., 2009); (Steel, 2010).”
BackgroundThe gut microbiome in atherosclerotic cardiovascular disease
Jie, Z., Xia, H., Zhong, S.-L., Feng, Q., Li, S., Liang, S., Zhong, H., Liu, Z., Gao, Y., Zhao, H., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00900-1 · Cited by 1,638 · cited 1×
“On the contrary, the brain can also control gastrointestinal function (Jie et al., 2017).”
BackgroundSelf-citationThe Gut Microbiota and Alzheimer’s Disease
Jiang, C., Li, G., Huang, P., Liu, Z., & Zhao, B. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161141 · Cited by 852
Self-citationLong-term benefit of microbiota transfer therapy on autism symptoms and gut microbiota
Kang, D.-W., Adams, J. B., Coleman, D. M., Pollard, E. L., Maldonado, J., McDonough-Means, S., Caporaso, J. G., & Krajmalnik-Brown, R. (2019) · Scientific Reports · doi:10.1038/s41598-019-42183-0 · Cited by 749
Interaction of gut microbiota with bile acid metabolism and its influence on disease states
Staley, C., Weingarden, A. R., Khoruts, A., & Sadowsky, M. J. (2017) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-016-8006-6 · Cited by 581
Gut microbiota mediates intermittent-fasting alleviation of diabetes-induced cognitive impairment
Liu, Z., Dai, X., Zhang, H., Shi, R., Hui, Y., Jin, X., Zhang, W., Wang, L., Wang, Q., Wang, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14676-4 · Cited by 549
Self-citationSun, J., Xu, J., Ling, Y., Wang, F., Gong, T., Yang, C., Ye, S., Ye, K., Wei, D., Song, Z., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0525-3 · Cited by 532
The neuropathology and cerebrovascular mechanisms of dementia
Raz, L., Knoefel, J., & Bhaskar, K. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.164 · Cited by 470
Antibiotics, gut microbiota, and Alzheimer’s disease
Angelucci, F., Cechova, K., Amlerova, J., & Hort, J. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1494-4 · Cited by 454 · cited 1×
“It has been pointed out that APP/PS1 transgenic mice treated with long-term high-dose antibiotic mixtures showed altered composition of gut microbiota and increased the neuroinflammatory state and therefore the disease itself (Angelucci et al., 2019).”
BackgroundAltered Gut Microbiota in a Mouse Model of Alzheimer’s Disease
Zhang, L., Wang, Y., Xiayu, X., Shi, C., Chen, W., Song, N., Fu, X., Zhou, R., Xu, Y.-F., Huang, L., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170020 · Cited by 449 · cited 1×
“On the one hand, gut microbiota and its metabolites destroy the gut barrier function, allowing its harmful microorganisms and some neurotoxic metabolites to enter the central nervous system while activating the immune system and inflammatory cells, which affect the behavior and function of the brain (Zhang et al., 201…”
BackgroundRelationship between the gut microbiome and brain function
Mohajeri, M. H., La Fata, G., Steinert, R. E., & Weber, P. (2018) · Nutrition Reviews · doi:10.1093/nutrit/nuy009 · Cited by 376
Mocanu, V., Zhang, Z., Deehan, E. C., Kao, D. H., Hotte, N., Karmali, S., Birch, D. W., Samarasinghe, K. K., Walter, J., & Madsen, K. L. (2021) · Nature Medicine · doi:10.1038/s41591-021-01399-2 · Cited by 328
The intestinal microbiome, probiotics and prebiotics in neurogastroenterology
Saulnier, D. M., Ringel, Y., Heyman, M. B., Foster, J. A., Bercik, P., Shulman, R. J., Versalovic, J., Verdu, E. F., Dinan, T. G., Hecht, G., et al. (2013) · Gut Microbes · doi:10.4161/gmic.22973 · Cited by 248
Insights into Butyrate Production in a Controlled Fermentation System via Gene Predictions
Esquivel-Elizondo, S., Ilhan, Z. E., Garcia-Peña, E. I., & Krajmalnik-Brown, R. (2017) · mSystems · doi:10.1128/msystems.00051-17 · Cited by 227
Hazan, S. (2020) · Journal of International Medical Research · doi:10.1177/0300060520925930 · Cited by 200 · cited 2×
“Hazan et al. have reported a case of an AD 02 patient treated with FMT (Hazan, 2020), in which the symptoms of cognitive impairment improved, and the Mini-Mental State Examination (MMSE) score increased from 20 to 26 (after 2 months) and 29 (after 6 months).”
MethodAbnormal gut microbiota composition contributes to cognitive dysfunction in SAMP8 mice
Zhan, G., Yang, N., Li, S., Huang, N., Fang, X., Zhang, J., Zhu, B., Yang, L., Yang, C., & Luo, A. (2018) · Aging · doi:10.18632/aging.101464 · Cited by 176
Guo, M., Peng, J., Huang, X., Xiao, L., Huang, F., & Zuo, Z. (2021) · Journal of Alzheimer's Disease · doi:10.3233/jad-201040 · Cited by 176
Wang, H., Zhang, M., Li, J., Liang, J., Yang, M., Xia, G., Ren, Y., Zhou, H., Wu, Q., He, Y., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02435-9 · Cited by 133
Self-citationZhang, Z., Yi, P., Yang, J., Huang, J., Xu, P., Hu, M., Zhang, C., Wang, B., & Peng, W. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.112371 · Cited by 116
A Blood-Based, 7-Metabolite Signature for the Early Diagnosis of Alzheimer's Disease
Olazarán, J., Gil-de-Gómez, L., Rodríguez-Martín, A., Valentí-Soler, M., Frades-Payo, B., Marín-Muñoz, J., Antúnez, C., Frank-García, A., Acedo-Jiménez, C., Morlán-Gracia, L., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-142925 · Cited by 115
Bowers, M., Liang, T., Gonzalez-Bohorquez, D., Zocher, S., Jaeger, B. N., Kovacs, W. J., Röhrl, C., Cramb, K. M. L., Winterer, J., Kruse, M., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.04.002 · Cited by 105
Owen, J. B., Di Domenico, F., Sultana, R., Perluigi, M., Cini, C., Pierce, W. M., & Butterfield, D. A. (2009) · Journal of Proteome Research · doi:10.1021/pr800667a · Cited by 100
Han, D., Li, Z., Liu, T., Yang, N., Li, Y., He, J., Qian, M., Kuang, Z., Zhang, W., Ni, C., et al. (2020) · Aging and disease · doi:10.14336/ad.2020.0106 · Cited by 99
Self-citationIncreased bilirubins and their derivatives in cerebrospinal fluid in Alzheimer’s disease
Kimpara, T., Takeda, A., Yamaguchi, T., Arai, H., Okita, N., Takase, S., Sasaki, H., & Itoyama, Y. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00128-7 · Cited by 90
Wen, K., Tao, L., Tao, Z., Meng, Y., Zhou, S., Chen, J., Yang, K., Da, W., & Zhu, Y. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.535310 · Cited by 76
Altered fecal microbiota composition in individuals who abuse methamphetamine
Yang, Y., Yu, X., Liu, X., Liu, G., Zeng, K., & Wang, G. (2021) · Scientific Reports · doi:10.1038/s41598-021-97548-1 · Cited by 68
Yu, F., Han, W., Zhan, G., Li, S., Xiang, S., Zhu, B., Jiang, X., Yang, L., Luo, A., Hua, F., et al. (2019) · Aging · doi:10.18632/aging.101978 · Cited by 65
A comprehensive approach to stool donor screening for faecal microbiota transplantation in China
He, J., He, X., Ma, Y., Yang, L., Fang, H., Shang, S., Xia, H., Lian, G., Tang, H., Wang, Q., et al. (2021) · Microbial Cell Factories · doi:10.1186/s12934-021-01705-0 · Cited by 58
Self-citationZhang, B., Yang, L., Ning, H., Cao, M., Chen, Z., Chen, Q., Lian, G., Tang, H., Wang, Q., Wang, J., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.02159-21 · Cited by 40
Self-citationAssociation of L-α Glycerylphosphorylcholine With Subsequent Stroke Risk After 10 Years
Lee, G., Choi, S., Chang, J., Choi, D., Son, J. S., Kim, K., Kim, S. M., Jeong, S., & Park, S. M. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.36008 · Cited by 37
Phylogenomics and Evolutionary Dynamics of the Family Actinomycetaceae
Zhao, K., Li, W., Kang, C., Du, L., Huang, T. L., Zhang, X., Wu, M., & Yue, B. (2014) · Genome Biology and Evolution · doi:10.1093/gbe/evu211 · Cited by 28
Drzazga, A. K., Okulus, M., Rychlicka, M., Biegała, Ł., Gliszczyńska, A., & Gendaszewska‐Darmach, E. (2020) · Nutrients · doi:10.3390/nu12041173 · Cited by 27
Madison, A. A., Belury, M. A., Andridge, R., Shrout, M. R., Renna, M. E., Malarkey, W. B., Bailey, M. T., & Kiecolt‐Glaser, J. K. (2020) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqaa085 · Cited by 23
Gotoh, K., Sakaguchi, Y. M., Kato, H., Osaki, H., Jodai, Y., Wakuda, M., Take, A., Hayashi, S., Morita, E., 杉江, 岳., et al. (2021) · Anaerobe · doi:10.1016/j.anaerobe.2021.102502 · Cited by 17
Fecal microbiota transplants may aid melanoma immunotherapy resistance
Fillon, M. (2021) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21676 · Cited by 11
Steel, K. (2010) · PubMed · Cited by 6
Cited by
Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases
Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, C. X., Chan, H. H., Yeow, S. H., Foo, J. B., Ong, Y. S., How, C. W., & Khaw, K. Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01743-1 · Cited by 1,193
Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances
Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02145-7 · Cited by 165
Self-citationAlzheimer’s Disease Detection Using Deep Learning on Neuroimaging: A Systematic Review
Alsubaie, M. G., Luo, S., & Shaukat, K. (2024) · Machine Learning and Knowledge Extraction · doi:10.3390/make6010024 · Cited by 185
Liang, Y., Liu, C., Cheng, M., Geng, L., Li, J., Du, W., Song, M., Chen, N., Yeleen, T. A. N., Li, S., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14057 · Cited by 83
Lista, S., Munafò, A., Caraci, F., Imbimbo, C., Emanuele, E., Minoretti, P., Pinto-Fraga, J., Merino-País, M., Crespo‐Escobar, P., López‐Ortiz, S., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102659 · Cited by 51
Metadata
- Authors
- Chen, X., Zhang, W., Lin, Z., Zheng, C., Chen, S., Zhou, H., & Liu, Z.
- Affiliations
- Guangdong Medical College (CN)
- Corresponding author
- Zhou, Haihong
- Liu, Zhou
- Venue
- Frontiers in Cellular and Infection Microbiology
- Publisher
- Frontiers Media SA
- Published
- 2023-04-11
- Volume
- 13
- Pages
- 1103189-1103189
- ISSN
- 2235-2988 (ISSN-L)
- PMC
- PMC10127103
- OpenAlex
- W4364365415
- Cited by
- 55
- References
- 38
- Citations by year
- 2026: 12 · 2025: 25 · 2024: 16 · 2023: 2
- FWCI
- 4.90
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Cellular and Infection Microbiology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Natural Science Foundation of Guangdong Province
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- fecal microbiota transplantation, mild cognitive impairment, gut microbiota, serum metabolomics, lipopolysaccharide-binding protein, bile secretion, choline metabolism, cognitive function, treatment safety, Alzheimer's disease, gut-brain axis, deoxycholic acid
- MeSH terms
- Fecal Microbiota Transplantation, Activities of Daily Living, Feces, Female, Humans, Pilot Projects, Treatment Outcome, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.